July 30, 2024 – Roche introduced the completion of the acquisition of LumiraDx’s Level of Care expertise, following receipt of all required antitrust and regulatory approvals. Roche will now start the total integration of the corporate’s modern multi-assay level of care platform and related R&D, operational and industrial websites into its world group.

With this acquisition, Roche enhances its diagnostics portfolio with an easy-to-use platform that consolidates a broad vary of immunoassay and scientific chemistry checks on a single instrument, with the potential to develop to molecular checks sooner or later. The modern answer permits Roche to additional develop its providing in decentralized affected person care and drive world entry to well timed and actionable diagnostic outcomes.

Discover out extra